Quick Answer
Kymera Therapeutics, Inc. reported Cash and Equivalents of $357.01 million for fiscal year 2025.
Kymera Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $357.01M | +196.9% |
| 2024 | $120.26M | +9.4% |
| 2023 | $109.97M | +60.8% |
| 2022 | $68.39M | +42.6% |
| 2021 | $47.98M | +54.7% |
| 2020 | $31.00M | -59.2% |
| 2019 | $76.02M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $112.95M | +2.0% | -66.4% |
| June 30, 2025 | $335.82M | +396.7% | +0.0% |
| March 31, 2025 | $335.82M | +259.1% | +179.3% |
| December 31, 2024 | $120.26M | +9.4% | +8.6% |
| September 30, 2024 | $110.72M | +36.6% | +63.8% |
| June 30, 2024 | $67.61M | +29.1% | -27.7% |
| March 31, 2024 | $93.51M | +86.5% | -15.0% |
| December 31, 2023 | $109.97M | +60.8% | +35.7% |
- Kymera Therapeutics, Inc. showed an increase of +196.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Kymera Therapeutics, Inc.’s cash and equivalents has grown by 369.7% (from $76.02 million to $357.01 million).
- The most recent figure is from Kymera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: